版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Th17 cells and psoriasis OutlineI. Effector cytokines and differentiation process of Th17 cells Pathogenesis of psoriasis related to Th17 cells A. Th17 cells and autoimmune diseases B. Introduction of psoriasis C. The inflammatory triangle in psoriasisTherapies against psoriasis targeting th17 cells
2、 A. Assessment criterion of therapeutic effectiveness in psoriasis B. Current FDA approved therapies for psoriasis C. Secukinumab (AIN-457) D. Further development of psoriasis treatment Figure1. Subsets of Th cellsFrom:Induction and effector functions of TH17 cellsNature, 2008(453):1Th17 cellsIL-22I
3、L-17A,FIL-21Effector cytokines of Th 17 cellsEffector cytokines of Th 17 cells: IL-17proinflammatorycytokines, chemokines and metalloproteinasessimilar function often expressed coordinately in Th17IL-17AIL-17FRecruitment of neutrophil cellsNK cellsTh17 cellsActivated T cellsIL-22Effector cytokines o
4、f Th 17 cells: IL-22the expression of -defensins in epithelial cellspromote epidermal hyperplasiaIL-21CD4+ T cells (stimulated by IL-6)Th 17 cellsT follicular helper cellsNK cellsproliferation and differentiation of CD8+ T cellsB-cell differentiation and antibody class switching differentiation/ampl
5、ification of TH17 cellsEffector cytokines of Th 17 cells: IL-21Figure2. The differentiation of TH17 cellsFrom:Induction and effector functions of TH17 cellsNature, 2008(453):1OutlineI. Effector cytokines and differentiation process of Th17 cells Pathogenesis of psoriasis related to Th17 cells A. Th1
6、7 cells and autoimmune diseases B. Introduction of psoriasis C. The inflammatory triangle in psoriasisTherapies against psoriasis targeting th17 cells A. Assessment criterion of therapeutic effectiveness in psoriasis B. Current FDA approved therapies for psoriasis C. Secukinumab (AIN-457) D. Further
7、 development of psoriasis treatment A. Th17 cells and autoimmune diseases Th17 in innate immunity:G+ bacteriaG- bacteriaFungiTh17 cellsOther subsets of T helper cellsSites of infectionFunction of cytokines:IL-17 :promote cartilage and bone destruction disrupt tight junctions of the bloodbrain barrie
8、r Increased IL-17Observed inRheumatoid arthritisMultiple sclerosisInflammatory bowel diseasepsoriasisIL-22IL-23acanthosisdermal inflammationdisrupt tight junction of BBBB. PsoriasisPsoriasis: an immune-mediated, genetic disease manifesting in the skin or joints or both.Comorbid diseases: psoriatic a
9、rthritis, cardiovascular disorders, Crohns disease, lymphomaFrom:Psoriasis. The Lancet. 2015, 386: 98394Figure3. Histopathological features of psoriasis dilated and contorted dermal blood vesselsmixed inflammatory infiltratewith neutrophilsmany T cells in the dermis (detection of CD3)dilated and con
10、torted dermal blood vesselsC. Plausible mechanism:Th 17 disease:Cross-talk between innate and adaptive immunityinterleukin-23/T helper cell 17 (Th17) axisA triangle between TNF, type I IFNs and IL-17Figure 4. The interplay between TNF and type I IFNs in psoriasistype I IFNs enhance their own product
11、ion and that of TNF, TNF silences type I IFN productionpDCbacterial insults Virus insultsStimulationFrom: An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17Cytokine & Growth Factor Reviews. 2015(26): 2533From: An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17Cytokine &
12、 Growth Factor Reviews. 2015(26): 2533Figure5. Normal skin and skin of patients on anti-TNF treatmentFigure 6. The interplay between TNF-IL17neutrophilCXCL1, CXCL2, CXCL5, IL-8lymphocytes neutrophils Langerhans cellsneutrophilsFrom: An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17Cy
13、tokine & Growth Factor Reviews. 2015(26): 2533Figure 7. The interplay between Type I IFN-IL-17Skin injurypDC -defensins S100 family proteinskerotinocyteFrom: An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17Cytokine & Growth Factor Reviews. 2015(26): 2533epidermal regeneration and wo
14、und healingFigure 9. Triangle of TNF, IL-17, and IFN From: An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17Cytokine & Growth Factor Reviews. 2015(26): 2533OutlineI. Effector cytokines and differentiation process of Th17 cells Pathogenesis of psoriasis related to Th17 cells A. Th17 c
15、ells and autoimmune diseases B. Introduction of psoriasis C. The inflammatory triangle in psoriasisTherapies against psoriasis targeting th17 cells A. Assessment criterion of therapeutic effectiveness in psoriasis B. Current FDA approved therapies for psoriasis C. Secukinumab (AIN-457) D. Further de
16、velopment of psoriasis treatment A. Assessment of therapeutic effectiveness in psoriasis: 1. Psoriasis Area and Severity Index (PASI) the degree of erythema, induration, scalingthe percent of body surface area (BSA) involvedMeaningful response to a given therapy: A reduction in the PASI score of at
17、least 75%PASI-75: the proportion of patients achieving 75% reduction by a certain time point2. The modified investigators global assessment (Modified IGA)Meaningful response to a given therapy: a score of 0 (clear) or 1 (almost clear)5-point instrument0: normal skin4: severe psoriasistopical agents
18、(steroidal and non-steroidal)ultravioletphototherapysystemic therapy immunosuppressive agents such as methotrexate and cyclosporineB. Current FDA approved therapies for psoriasisBiologic agents TNF-alpha inhibitors :Etanercept, Infliximab, AdalimumabPhosphodiesterase 4 inhibitor:ApremilastIL-12/IL-2
19、3p40 inhibitor: Briakinumab IL-6 pathway inhibitor: OlokizumabFigure10. Drugs targeting Th17 pathways and their use in human diseasesFrom:The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases Arch. Immunol. Ther. Exp. 2015 (63):435449Recently FDA-approved: IL-17A inhibitor:Secukinumab (AIN-4
20、57)Immunogenicity:very few cases of anti-secukinumab antibody formationanti-secukinumab antibodies not related to reduced efficacySecukinumab (AIN-457)Pharmacokinetics:Bioavailability with subcutaneous administration : 55 to 77%Volume of distribution in interstitial fluid of skin : 27 to 40% of that
21、 in serum (after a single subcutaneous dose of 300 mg)Half-life: 22 to 31 daysParameters increase in higher body weightsA phase III clinical trailFIXTURE:Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in PsoriasisStudy design:double-
22、blind, both placebo- and active-controlled 52-week 1306 patients25%-secukinumab at a dose of 300 mg25%-secukinumab at a dose of 150 mg25%- etanercept at a dose of 50mg25%-placebo at a dose of 50 mgSecukinumab: once weekly for 5 weeks, then every 4 weeksPlacebo or etanercept: twice weekly for 12 week
23、s, then once weeklyFrom: Secukinumab in Plaque Psoriasis Results of Two Phase 3 TrialsN Engl J Med 2014(371):326-38.Figure 11. Speed of Response in FIXTURE studyFigure 12. Efficacy over 52 weeksFrom: Secukinumab in Plaque Psoriasis Results of Two Phase 3 TrialsN Engl J Med 2014(371):326-38.Conclusio
24、nthe superior efficacy of secukinumab over the TNF inhibitor etaneceptclinical response occurred more rapidly with secukinumabinterleukin-17A as an important therapeutic target in psoriasisHigh efficacy of secukinumabsuperiority over other biologics (etanercept, ustekinumab)300 mg subcutaneous dose:
25、 PASI-75 80% PASI-90 55%150 mg subcutaneous dose: PASI-75 70% PASI-90 40% Existing therapiesPASI-75methotrexate and cyclosporine40-70%TNF-inhibitorinfliximab50-80%adalimumabetanerceptacitretin30-50%apremilast30%Table 1. Pre-existing therapies with a wide range of clinical efficacyD. Further developm
26、ent of psoriasis treatmentfind new targeted pathways with high efficacydevelop etiological and personalized therapy stratify people with psoriasis into populations(based on etiology) target specific dysfunctional pathway in patients Problem: no response to a specific biologic agentResolution:Figure
27、9. Triangle of TNF, IL-17, and IFN From: An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17Cytokine & Growth Factor Reviews. 2015(26): 2533Reference:Bettelli, E., Korn, T. & Oukka, M. ,et al. Induction and effector functions of TH17 cells. Nature. 2008, 453(7198): 1051-1057Yang, J., S
28、undrud, M. S. & Skepner, J., Targeting Th17 cells in autoimmune diseases. Trends in Pharmacological Sciences. 2014, 35(10): 493-500Yamagata, T., Skepner, J.& Yang, J., Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases. Archivum Immunologiae et Therapiae Experimentalis, 2015,
29、 63(6): 405-414Tabarkiewicz, J., Pogoda, K., Karczmarczyk, et al. The Role of IL-17 and Th17 Lymphocytes in Autoimmune Diseases. Archivum Immunologiae et Therapiae Experimentalis, 2015, 63(6): 435-449Langley, R. G., Elewski, B. E., Lebwohl, M.,et al. Secukinumab in Plaque Psoriasis Results of Two Phase 3 Trials. New England Journal of Medicine, 2014, 371(4): 326-338Jaleel, T., Elmets, C., Weinkle, A., et al. Secukinumab (AIN-4
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 六年級(jí)上冊(cè)信息技術(shù)人教版第5課 用重復(fù)命令畫(huà)圖(教案)
- FSC管理手冊(cè)資料
- Lesson 4 He goes to school at 7:30. Period 1 教學(xué)設(shè)計(jì)-2024-2025學(xué)年接力版英語(yǔ)五年級(jí)上冊(cè)
- 2024年度海南省安全員之C證(專職安全員)典型題匯編及答案
- 北師大版生物八年級(jí)上冊(cè) 第20章 第1節(jié) 遺傳和變異現(xiàn)象(1)(教案)
- 2024滅火排煙機(jī)器人
- 河北省保定市涿州市實(shí)驗(yàn)中學(xué)2024-2025學(xué)年九年級(jí)上學(xué)期第一次月考數(shù)學(xué)試題
- 浙江省湖州市吳興區(qū)十校2024屆中考二模數(shù)學(xué)試題含解析
- 寫(xiě)給外星人的一封信20篇
- 學(xué)生干部個(gè)人反思剖析材料
- 2024-2025學(xué)年全國(guó)中學(xué)生天文知識(shí)競(jìng)賽考試題庫(kù)(含答案)
- (2024年)傳染病培訓(xùn)課件
- 第8課《列夫-托爾斯泰》-統(tǒng)編版語(yǔ)文八年級(jí)上冊(cè)
- 高處作業(yè)吊籃施工安全監(jiān)理實(shí)施細(xì)則
- GB 18613-2020電動(dòng)機(jī)能效限定值及能效等級(jí)
- 裝飾裝修工程技術(shù)標(biāo)
- 軌道交通地鐵站主體結(jié)構(gòu)質(zhì)量缺陷專項(xiàng)處理方案
- 幼兒園小班科學(xué):《動(dòng)物花花衣》 課件
- JGJ_T139-2020玻璃幕墻工程質(zhì)量檢驗(yàn)標(biāo)準(zhǔn)(高清-最新版)
- 干制食用菌作業(yè)指導(dǎo)書(shū)(共13頁(yè))
- 工程施工畢業(yè)設(shè)計(jì)(鋼筋混凝土專項(xiàng)施工方案)
評(píng)論
0/150
提交評(píng)論